Eton Pharmaceuticals (NASDAQ:ETON – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a report released on Wednesday, Benzinga reports. They presently have a $9.00 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 95.65% from the stock’s current price.
Eton Pharmaceuticals Stock Performance
Eton Pharmaceuticals stock opened at $4.60 on Wednesday. Eton Pharmaceuticals has a 52 week low of $3.03 and a 52 week high of $5.81. The stock has a market cap of $118.86 million, a price-to-earnings ratio of 115.00 and a beta of 1.29. The company’s 50-day moving average price is $3.75 and its two-hundred day moving average price is $3.73.
Eton Pharmaceuticals (NASDAQ:ETON – Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.05). The firm had revenue of $9.07 million for the quarter, compared to the consensus estimate of $10.00 million. Eton Pharmaceuticals had a negative return on equity of 43.62% and a negative net margin of 21.31%.
Institutional Inflows and Outflows
About Eton Pharmaceuticals
Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.
Read More
- Five stocks we like better than Eton Pharmaceuticals
- What is Insider Trading? What You Can Learn from Insider Trading
- Marvell Technology AI Boom is Just Getting Started with ASIC
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Trends Investors Should Watch This Quarter for Market Insights
- What Is WallStreetBets and What Stocks Are They Targeting?
- Homebuilders Poised for a Breakout: Top Stocks to Watch
Receive News & Ratings for Eton Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eton Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.